Ari Green

List of Publications by Year in Descending Order

82 papers	4,095 citations	28 h-index	63 g-index
90 ext. papers	5,482 ext. citations	9.6 avg, IF	5.29 L-index

#	Paper	IF	Citations
82	Blood GFAP as an emerging biomarker in brain and spinal cord disorders.. *Nature Reviews Neurology* , **2022**,	15	9
81	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. *Multiple Sclerosis and Related Disorders*, **2022**, 57, 103356	4	2
80	Characterizing Fixational Eye Motion Variance Over Time as Recorded by the Tracking Scanning Laser Ophthalmoscope.. *Translational Vision Science and Technology*, **2022**, 11, 35	3.3	1
79	Reply to "Spinal cord atrophy is a preclinical marker of progressive MS".. *Annals of Neurology*, **2022**,	9.4	
78	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial.. *Multiple Sclerosis and Related Disorders*, **2022**, 61, 103747	4	0
77	Reply to "Interpretation of longitudinal changes of the inner nuclear layer in MS".. *Annals of Neurology*, **2022**,	9.4	0
76	Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.. *Neurology: Neuroimmunology and NeuroInflammation*, **2022**, 9,	9.1	2
75	Spinal cord atrophy predicts progressive disease in relapsing multiple sclerosis. *Annals of Neurology* , **2021**,	9.4	6
74	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. *Annals of Clinical and Translational Neurology*, **2021**, 8, 2235	5.3	3
73	MRI findings in blinded trials should be available to treating physicians - Commentary. *Multiple Sclerosis Journal*, **2021**, 27, 816-817	5	
72	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. *Neurology*, **2021**, 97, 68-79	6.5	19
71	Artificial intelligence extension of the OSCAR-IB criteria. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1528-1542	5.3	3
70	Distinctive waves of innate immune response in the retina in experimental autoimmune encephalomyelitis. *JCI Insight*, **2021**, 6,	9.9	4
69	Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. *Annals of Neurology*, **2021**, 89, 192-193	9.4	8
68	Underutilization of physical therapy for symptomatic women with MS during and following pregnancy. *Multiple Sclerosis and Related Disorders*, **2021**, 48, 102703	4	2
67	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. *Multiple Sclerosis Journal*, **2021**, 27, 2052-2061	5	4
66	Socioeconomic disadvantage in multiple sclerosis: does inequality act on the substrate for disability?. *Brain*, **2021**, 144, 3552-3554	11.2	

65	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. *American Journal of Neuroradiology*, **2020**, 41, 2219-2226	4.4	5
64	Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 343-353	5	7
63	Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. *Nature Immunology*, **2020**, 21, 513-524	19.1	51
62	Importance of Not MSing Cerebral White Matter Disease in Patients with Inflammatory Bowel Disease. *Digestive Diseases and Sciences*, **2020**, 65, 2527-2532	4	
61	Imaging correlates of visual function in multiple sclerosis. *PLoS ONE*, **2020**, 15, e0235615	3.7	2
60	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. *Brain*, **2020**, 143, 1127-1142	11.2	17
59	Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615		
58	Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615		
57	Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615		
56	Imaging correlates of visual function in multiple sclerosis **2020**, 15, e0235615		
55	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. *Lancet, The*, **2019**, 394, 1352-1363	40	247
54	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e533	9.1	11
53	Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors. *Journal of Neuroscience*, **2019**, 39, 2184-2194	6.6	24
52	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. *JAMA Network Open*, **2019**, 2, e190570	10.4	37
51	Silent progression in disease activity-free relapsing multiple sclerosis. *Annals of Neurology*, **2019**, 85, 653-666	9.4	135
50	Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. *Journal of Visualized Experiments*, **2019**,	1.6	8
49	Color perception impairment following optic neuritis and its association with retinal atrophy. *Journal of Neurology*, **2019**, 266, 1160-1166	5.5	4
48	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 1526-1534	5	32

47	Early complement genes are associated with visual system degeneration in multiple sclerosis. *Brain*, **2019**, 142, 2722-2736	11.2	13
46	Lessons from an unsuccessful therapeutic trial. *Lancet Neurology, The*, **2019**, 18, 808-810	24.1	
45	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. *Journal of Neuroinflammation*, **2019**, 16, 203	10.1	15
44	Subclinical Saccadic Eye Movement Dysfunction in Pediatric Multiple Sclerosis. *Journal of Child Neurology*, **2019**, 34, 38-43	2.5	6
43	Potential Benefits of Early Aggressive Treatment in Multiple Sclerosis. *JAMA Neurology*, **2019**, 76, 254-256	17.2	1
42	Harnessing electronic medical records to advance research on multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 408-418	5	15
41	OCT is an alternative to MRI for monitoring MS - Commentary. *Multiple Sclerosis Journal*, **2018**, 24, 705-706	5	2
40	Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e453	9.1	114
39	Reduced contrast sensitivity among older women is associated with increased risk of cognitive impairment. *Annals of Neurology*, **2018**, 83, 730-738	9.4	36
38	Oligodendrocyte-encoded Kir4.1 function is required for axonal integrity. *ELife*, **2018**, 7,	8.9	43
37	Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e505	9.1	19
36	Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients. *MBio*, **2018**, 9,	7.8	33
35	Sex differences and subclinical retinal injury in pediatric-onset MS. *Multiple Sclerosis Journal*, **2017**, 23, 447-455	5	17
34	Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. *Science Translational Medicine*, **2017**, 9,	17.5	107
33	Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. *Neurobiology of Aging*, **2017**, 51, 141-147	5.6	29
32	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. *Lancet, The*, **2017**, 390, 2481-2489	40	221
31	Remyelinating Pharmacotherapies in Multiple Sclerosis. *Neurotherapeutics*, **2017**, 14, 894-904	6.4	27
30	Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. *Neurology*, **2017**, 89, 2092-2100	9.9	97

29	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. *BMJ Open Ophthalmology*, **2017**, 1, e000008	3.2	8
28	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurology, The*, **2017**, 16, 797-812	24.1	243
27	Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. *Journal of Visualized Experiments*, **2017**,	1.6	3
26	Systematic integration of biomedical knowledge prioritizes drugs for repurposing. *ELife*, **2017**, 6,	8.9	151
25	T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury. *Journal of Nature and Science*, **2017**, 3,		6
24	Long-term evolution of multiple sclerosis disability in the treatment era. *Annals of Neurology*, **2016**, 80, 499-510	9.4	229
23	Author response: Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery **2016**,		3
22	Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. *ELife*, **2016**, 5,	8.9	128
21	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 14781-14786	11.5	44
20	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. *Neurology*, **2016**, 86, 2303-9	6.5	240
19	Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. *Journal of Neurology*, **2016**, 263, 1323-31	5.5	78
18	Neurologic Complications of Common Variable Immunodeficiency. *Journal of Clinical Immunology*, **2016**, 36, 793-800	5.7	18
17	Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination. *Journal of Neuroscience*, **2016**, 36, 7925-35	6.6	66
16	Encephalitis of unclear origin diagnosed by brain biopsy: a diagnostic challenge. *JAMA Neurology*, **2015**, 72, 66-72	17.2	17
15	Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2015**, 4, 304-10	4	11
14	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. *JAMA Neurology*, **2015**, 72, 897-904	17.2	63
13	Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. *Journal of Experimental Medicine*, **2014**, 211, 1937-45	16.6	67
12	Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. *Nature Medicine*, **2014**, 20, 954-960	50.5	339

11	Retinal architecture and mfERG: Optic nerve head component response characteristics in MS. *Neurology*, **2014**, 82, 1888-96	6.5	10
10	A randomized controlled phase II trial of riluzole in early multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2014**, 1, 340-7	5.3	28
9	Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2014**, 3, 720-7	4	21
8	Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. *Lancet Neurology, The*, **2012**, 11, 963-72	24.1	216
7	Microcystic macular oedema in multiple sclerosis is associated with disease severity. *Brain*, **2012**, 135, 1786-93	11.2	239
6	Vitamin B12 is inversely correlated with latency of multifocal visual evoked potential in healthy older adults. *FASEB Journal*, **2011**, 25, 97.2	0.9	
5	Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. *Brain*, **2010**, 133, 1591-601	11.2	302
4	Suprasellar germinoma and late perioptic seeding. *European Journal of Ophthalmology*, **2008**, 18, 159-61	1.9	5
3	Rephetio: Repurposing drugs on a hetnet [project]		3
2	Rephetio: Repurposing drugs on a hetnet [proposal]		2
1	Systematic integration of biomedical knowledge prioritizes drugs for repurposing		1